8-K: Mineralys Therapeutics Announces Positive Q1 2025 Results and Corporate Update, Highlighting Successful Hypertension Trials

Mineralys Therapeutics reported positive topline results from pivotal hypertension trials and provided a corporate update, including financial results for the first quarter ended March 31, 2025.

Summary

• Mineralys Therapeutics announced its financial results for the first quarter ended March 31, 2025, along with a corporate update.
• The company's pivotal Advance-HTN and Launch-HTN trials achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile.
• Topline data from the Explore-CKD Phase 2 trial is anticipated in Q2 2025.
• The Explore-OSA Phase 2 trial was initiated in Q1 2025.
• The Launch-HTN trial reported a 16.9 mmHg reduction in systolic blood pressure with the 50 mg dose of lorundrostat, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) at week six.
• This benefit was sustained through week 12, with a 19.0 mmHg reduction in automated office systolic blood pressure and an 11.7 mmHg placebo-adjusted reduction (p-value <0.0001).
• The Advance-HTN trial reported a 15.4 mmHg absolute reduction in systolic blood pressure and a 7.9 mmHg placebo-adjusted reduction (p-value = 0.001) with the 50 mg dose, as assessed by 24-hour ambulatory blood pressure monitoring at 12 weeks.
• The company completed a public equity financing for gross proceeds of approximately $201.2 million on March 18, 2025.
• Cash, cash equivalents, and investments totaled $343.0 million as of March 31, 2025.
• The company believes its current cash will fund planned clinical trials, regulatory activities, and corporate operations into 2027.
• The net loss for the quarter ended March 31, 2025, was $42.2 million, compared to $31.5 million for the same period in 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with successful clinical trial results and a strong financial position, although the increased net loss tempers the overall sentiment slightly.

Positives

• Successful completion of pivotal trials for lorundrostat in hypertension.
• Favorable safety and tolerability profile demonstrated in clinical trials.
• Strong cash position of $343.0 million to fund future operations.
• Appointment of experienced Chief Commercial Officer, Eric Warren.
• Anticipated pre-NDA meeting with the FDA in Q4 2025.

Negatives

• Net loss of $42.2 million for the quarter ended March 31, 2025, which is higher than the $31.5 million loss for the same period in 2024.
• Increased R&D and G&A expenses compared to the previous year.

Risks

• The company's future performance is dependent entirely on the success of lorundrostat.
• Delays in clinical trials and nonclinical studies could impact timelines.
• The FDA may not deem the results of clinical trials sufficient for NDA submission or approval.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat could limit its development.
• The company relies on a license agreement with Mitsubishi Tanabe Pharma for intellectual property rights.

Future Outlook

The company anticipates a pre-NDA meeting with the FDA in the fourth quarter of 2025 and expects its current cash to fund operations into 2027.

Management Comments

• With the success of our two pivotal trials, we are working toward submitting our new drug application with a pre-NDA meeting with the FDA anticipated in the fourth quarter of 2025, stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.

Industry Context

Mineralys Therapeutics is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, addressing a significant unmet need in these therapeutic areas.

Comparison to Industry Standards

• The reported reduction in systolic blood pressure in the Launch-HTN and Advance-HTN trials appears competitive with other hypertension treatments.
• The favorable safety and tolerability profile of lorundrostat could differentiate it from existing therapies.
• Other companies developing treatments for hypertension include Novartis (Entresto), AstraZeneca (Atacand), and Johnson & Johnson (Invokana).
• Mineralys is also targeting CKD and OSA, which expands their potential market beyond hypertension alone.

Management Changes

Stakeholder Impact

• Shareholders: Positive results from clinical trials and a strong cash position are likely to be viewed favorably.
• Patients: Successful development of lorundrostat could provide a new treatment option for hypertension, CKD, and OSA.
• Employees: The company's growth and success could lead to job security and opportunities for advancement.
• Partners: Positive clinical trial results could attract potential partners for commercialization and further development.

Next Steps

• Submit a new drug application (NDA) to the FDA.
• Prepare for a pre-NDA meeting with the FDA in the fourth quarter of 2025.
• Continue the Transform-HTN open-label extension trial.
• Await topline data from the Explore-CKD Phase 2 trial in Q2 2025.
• Continue the Explore-OSA Phase 2 trial.

Key Dates

Keywords

lorundrostat, hypertension, clinical trials, Mineralys Therapeutics, financial results, aldosterone, CKD, OSA